Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration

BACKGROUND: Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance. Teicoplanin may represent an alternative to vancomycin because of its acceptable bone penetration and p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Infect Dis
Autors principals: Peeters, Olivier, Ferry, Tristan, Ader, Florence, Boibieux, André, Braun, Evelyne, Bouaziz, Anissa, Karsenty, Judith, Forestier, Emmanuel, Laurent, Frédéric, Lustig, Sébastien, Chidiac, Christian, Valour, Florent
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5093939/
https://ncbi.nlm.nih.gov/pubmed/27809799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-1955-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars